Pulmonary Fibrosis Study
What is Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a disease of inflammation that results in scarring, or fibrosis, of the lungs. In time, this fibrosis can build up to the point where the lungs are unable to provide oxygen to the tissues of the body. Doctors use the word "idiopathic" (from the Greek "idio" meaning "peculiar" or "unusual" and "pathy" meaning "illness") to describe the disease, because the cause of IPF is unknown. Currently, researchers believe that IPF may result from either an autoimmune disorder, a condition in which the body's immune system attacks its own tissues, or the after effects of an infection, most likely a virus. Whatever the trigger is for IPF, it appears to set off a series of events in which the inflammation and immune activity in the lungs--and, eventually, the fibrosis processes, too--become uncontrollable. In a few cases, heredity appears to play a part, possibly making some individuals more likely than others to get IPF. In studies of patients with IPF, the average survival rate has been found to be 4 to 6 years after diagnosis. Those who develop IPF at a young age seem to have a longer survival.
MedImmune: a Phase 2, Randomized Dose-ranging Study up to 68 weeks of treatment to Evaluate the Efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis.
PANTHER: a one-year study testing Prednisone, N-acetylcysteine and Azathioprine to evaluate its effect on IPF. -Closed to enrollment
FIBROGEN: a 45-week study to determine the safety of FG-3019 in subjects with IPF. (Idiopathic Pulmonary Fibrosis) -Closed to enrollment
BIPI 1199.34: a 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline, in patients with Idiopathic Pulmonary Fibrosis (IPF). -Closed to enrollment
PIPF-016: a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Learn more about the Intermune study. -Closed to enrollment
ROCHE: a new injectable study drug given every 4 weeks to slow the progression of IPF, study could last from 1 to 2.5 years.
RAINIER: a placebo controlled study involving new weekly injectable drug (GS-6624) to slow the progression of IPF, study could last up to 3-1/2 yrs.
BMS: a study involving a new oral medication to reduce the rate of decline in your forced vital capacity (FVC). Study will last approximately 34 weeks.
All qualified participants will receive at no cost, study related physical exam, medical care and medications.
If you are interested in the study or more information, contact the CardioPulmonary Research Center at 314-439-LUNG (5864).